- Author:
Li HAN
1
;
Xiao-Juan GUO
1
;
Rui-Juan DU
1
;
Yi CHEN
1
;
Qing-Lin FEI
1
;
Ke-Lei GUO
1
;
Hua BIAN
1
;
Li HAN
2
;
Rui-Juan DU
2
;
Ke-Lei GUO
2
;
Hua BIAN
2
Author Information
- Publication Type:Journal Article
- Keywords: albiflorin; multidrug resistance; MYC; ovarian cancer; P-glycoprotein; WW domain-containing ubiquitin E3 ligase1
- From: Chinese Pharmacological Bulletin 2023;39(2):268-274
- CountryChina
- Language:Chinese
- Abstract: Aim To study the reversal effect of albiflorin(AL)on multidrug resistance of human ovarian cancer and the potential mechanism. Methods The drug resistance reversal effect of AL on SKOV3/DDP cells was detected by CCK-8 kit,and the effect of AL on P-glycoprotein(P-gp)function was detected by flow cytometry. The effects of AL on MYC,WWP1 and ABCB1 in SKOV3/DDP cells were detected by RT-qPCR and Western blot. The MYC-knockdown SKOV3/DDP cell line was constructed by RNA interference technology,and its drug resistance,P-gp function and related gene and protein expression changes were investigated. Results AL had a drug resistance reversal effect on SKOV3/DDP cells and a concentration-dependent inhibitory effect on P-gp function. The inhibitory effects of AL 25,50 and 100 μmol·L-1 on ABCB1/P-gp,MYC and WWP1 were gradually enhanced. The inhibitory effect of MYCi975,a MYC inhibitor,on ABCB1/P-gp,MYC and WWP1 was stronger than or equivalent to that of AL 100 μmol·L-1 group. After knockdown of MYC in SKOV3/DDP cells,cell drug resistance,P-gp function,and related gene and protein expression were inhibited. Conclusions The drug resistance reversal effect of AL on SKOV3/DDP cells may be related to the inhibition of P-gp function and the expression of ABCB1/P-gp,MYC and WWP1,which provides an experiment base for the development of AL as a drug resistance reversal agent for the clinical treatment of ovarian cancer.